-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Central Committee of the Communist Party of China and the State Council issued the "Healthy China 2030" Planning Outline in 2016.
In order to fully respond to the planning goals of "Healthy China 2030" and further implement the concept of comprehensive and full-cycle maintenance and protection of people’s health, sponsored by China Cancer Foundation, National Cancer Center, Beijing Society for Breast Disease Prevention and Treatment, Boao Tumor Innovation Institute, China The "2021 China Cancer Health Management Conference and the 5th Chief Expert Forum on Breast Cancer Management and Management of Breast Cancer" hosted by the Cancer Hospital of the Academy of Medical Sciences, the State Key Laboratory of Molecular Oncology, and the China Cancer Health Management Institute were held.
According to the latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, China will have 416,371 new cases of breast cancer in 2020, accounting for 19.
At this conference, many breast cancer subject leaders, experts, and guests also jointly launched the "Healthy China·Critical Decade of Breast Cancer Action" (HC-ABC project), taking China's breast cancer standardized diagnosis and treatment capacity improvement and quality control level promotion as an example The core, focusing on the four dimensions of quality control system construction, quality control research results transformation, standardized diagnosis and treatment capacity building, and the formation of the "Annual Report on Standardized Diagnosis and Treatment of Breast Cancer in China".
In this regard, Professor Ma Fei pointed out: “Breast cancer, which is the number one incidence of female malignant tumors, uses its single-disease quality control as the starting point.
Professor Ying Jianming of the Department of Pathology, Cancer Hospital of the Chinese Academy of Medical Sciences introduced that in terms of discipline construction, the overall situation in China is that the quality of pathology reports is different from the standard level.
Professor Wu Xinhong from Hubei Cancer Hospital said that patient follow-up and its management mechanism are crucial to the protection of patients' treatment effect, the monitoring and active management of the individual's overall health.
Professor Jin Feng from the Department of Breast Surgery of the First Affiliated Hospital of China Medical University emphasized that multidisciplinary diagnosis and treatment (MDT) plays a vital role in the overall management of breast cancer.
